Low-dose, sequenced, individualized chemotherapy dosing method

• US 20060199189A1
• Filed: 03/07/2005
• Published: 09/07/2006
• Est. Priority Date: 03/07/2005
• Status: Abandoned Application

• Current Assignee: ORT, Inc.
• Original Assignee: ORT, Inc.
• Inventors: Bradford, Sherry A.
• Application Number:
  US11/073,925
• Publication Number:
  US 20060199189A1
• Time in Patent Office: Days
• US Class Current: 435/6.16
• CPC Class Codes: G01N 33/574 for cancer

Abstract

A low-dose, sequenced, individualized chemotherapy dosing method wherein an identification is made of biomorphomolecular markers associated with a patient tumor to be treated, and a percentage of tumor cells expressing each of the biomorphomolecular markers is determined. A set of drugs is selected that are adapted to target the biomorphomolecular markers. A percent of peak plasma concentration is determined for each drug based on the percentage of cells respectively expressing each biomorphomolecular marker. The drugs are administered according to drug dosages based on the respective concentrations. The method further includes selecting a drug treatment period, selecting a drug repetition cycle within the drug treatment period, determining a drug dosage for each drug based on its concentration and the number of repetition cycles, determining a drug sequence to be given during each cycle, and determining a dosing time for each drug.

Claims

1. A low-dose, sequence dripped, individualized chemotherapy dosing method, comprising:

identifying biomorphomolecular markers associated with patient tumor to be treated;

determining a percentage of tumor cells expressing each of said biomorphomolecular markers;

selecting a set of drugs adapted to target said biomorphomolecular markers;

determining a percent of peak plasma concentration for each of said drugs based on said percentage of cells respectively expressing said biomorphomolecular markers; and

administering said drugs according to drug dosages based on said percent of peak plasma concentration.

2. A method in accordance with claim 1 further including seleting a drug treatment period over which said drugs are given.

3. A method in accordance with claim 2 further including selecting a drug repetition cycle within said drug treatment period.

4. A method in accordance with claim 3 wherein said drug dosages are based on said percent of peak plasma concentration for each of said drugs and the number of said repetition cycles that will occur during said drug treatment period.

5. A method in accordance with claim 4 further including selecting a sequence of said drugs to be given during each of said drug repeition cycles.

6. A method in accordance with claim 5 further including selecting a dosing time for each of said drugs to be given during said sequences.

7. A method in accordance with claim 6 wherein said drugs are administered according to said drug dosages, said sequence of drugs and said dosing times during each of said drug repetition cycles until said drug treatment period has expired.

8. A method in accordance with claim 2 wherein said drug treatment period is selected to achieve a desired log-kill.

9. A method in accordance with claim 8 wherein said drug treatement period is approximately one seven-day week.

10. A method in accordance with claim 3 wherein said drug repetition cycle is selected based on consideration of tumor cell cycle.

11. A method in accordance with claim 10 wherein said drug repetition cycle is approximately one twenty-four hour day.

12. A method in accordance with claim 5 said drug seqeunce is selected based on consideration of drug synergy, additivity and inhibition.

13. A method in accordance with claim 5 wherein said drug sequence is selected based on said percent of peak plasma concentration for each of said drugs.

14. A method in accordance with claim 5 wherein said drug sequence is varied for each of said repetition cycles.

15. A method in accordance with claim 5 wherein said drug sequence is varied for each of said repetition cycles so that a drug that was first to be administered in a repetition cycle n-1 is last to be administered in next repetition cycle n.

16. A method in accordance with claim 6 wherein said dosing time is determined by said repetition cycle divided by the number of said drugs to be administered.

17. A method in accordance with claim 16 wherein said dosing time is determined based said repetition cycle including one or more rest periods.

18. A method in accordance with claim 1 wherein said drugs are sequenced by way of infusion pumping with automated control to selectively adminster each of said drugs at different times.

19. A low-dose, sequence dripped, individualized chemotherapy dosing method, comprising:

identifying biomorphomolecular markers associated with patient tumor to be treated;

determining a percentage of tumor cells expressing each of said biomorphomolecular markers;

selecting a set of drugs adapted to target said biomorphomolecular markers;

determining a percent of peak plasma concentration for each of said drugs based on said percentage of cells respectively expressing said biomorphomolecular markers;

selecting a drug treatment period;

selecting a drug repetition cycle within said drug treatment period;

determining a drug dosage for each of said drugs based on said percent of peak plasma concentration for each of said drugs and the number of said repetition cycles that will occur during said drug treatment period;

determining a sequence of said drugs to be given during each of said drug repeition cycles;

determining a dosing time for each of said drugs; and

administering said drugs according to said drug dosages, said sequence of drugs, and said dosing times during each of said drug repetition cycles until said drug treatment period has expired.

20. A low-dose, sequence dripped, individualized chemotherapy dosing method, comprising:

identifying biomorphomolecular markers associated with patient tumor to be treated;

determining a percentage of tumor cells expressing each of said biomorphomolecular markers;

selecting a set of drugs adapted to target said biomorphomolecular markers;

determining a percent of peak plasma concentration for each of said drugs based on said percentage of cells respectively expressing said biomorphomolecular markers;

selecting a drug treatment period;

selecting a drug repetition cycle within said drug treatment period;

determining a drug dosage for each of said drugs based on said percent of peak plasma concentration for each of said drugs and the number of said repetition cycles that will occur during said drug treatment period;

determining a sequence of said drugs to be given during each of said drug repeition cycles;

determining a dosing time for each of said drugs; and

administering said drugs according to said drug dosages, said sequence of drugs and said dosing times during each of said drug repetition cycles until said drug treatment period has expired;

said drug treatment period being selected to achieve a desired log-kill and being approximately one seven-day week;

said drug repetition cycle being selected based on consideration of tumor cell cycle and being approximately one twenty-four hour day;

said drug seqeunce being selected based on consideration of drug synergy, additivity and inhibition or based on said percent of peak plasma concentration for each of said drugs;

said drug sequence being varied for each of said repetition cycles so that a drug that was first to be administered in a repetition cycle n-1 is last to be administered in next repetition cycle n;

said dosing time being determined by said repetition cycle divided by the number of said drugs to be administered and taking into account rest periods allocated for said repeition, if any; and

said drugs being sequenced by way of infusion pumping with automated control to selectively adminster each of said drugs at different times.